Trial Profile
A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Birabresib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Merck & Co; OncoEthix
- 07 May 2018 Results published in the Journal of Clinical Oncology
- 24 Mar 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.